LONDON, UK: RTW Venture Fund’s portfolio company, Acelyrin, Inc. announced the pricing of its initial public offering (IPO) and admission to trade on Nasdaq Global Market under the ticker symbol “SLRN.”

The IPO raised $540 million by offering 30 million shares at $18.00 per share. The company’s share price traded up by 30.55% on the first day of trading to close at $23.50 per share.

Acelyrin is a late-stage clinical biopharma company that focuses on accelerating the development and delivery of transformative medicines in immunology. Its lead product candidate, Izokibep, is a small protein therapeutic designed to inhibit interleukin-17A (IL-17A) with high potency and the potential for robust tissue penetration. Izokibep is in late-stage clinical development across multiple indications, including hidradenitis suppurative, psoriatic arthritis, uveitis, and axial spondylarthritis.

Before the IPO, the Investment Manager, along with other funds managed by RTW Investments, LP, participated in Acelyrin’s $250 million Series B financing round in November 2021.

Roderick Wong, MD, Managing Partner and Chief Investment Officer at the Investment Manager, expressed his excitement about Acelyrin’s successful debut on the public markets, calling it the third successful debut from their portfolio this year, despite the challenging capital market. He also expressed his commitment to supporting the company’s efforts to develop new treatments for inflammatory conditions.

Kin and Carta has acquired Edinburgh-based Forecast Data

Alibaba’s logistics arm eyes up to $2 billion Hong Kong IPO in 2024